In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Zenas Biopharma Inc’s stock clocked out at $6.77, down -12.65% from its previous closing price of $7.75. In other words, the price has decreased by -$12.65 from its previous closing price. On the day, 0.52 million shares were traded.
Ratios:
To gain a deeper understanding of ZBIO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.21 and its Current Ratio is at 6.21. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wedbush on March 20, 2025, initiated with a Outperform rating and assigned the stock a target price of $35.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $19.
On December 16, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.H.C. Wainwright initiated its Buy rating on December 16, 2024, with a $30 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when MOULDER LEON O JR bought 25,000 shares for $6.67 per share. The transaction valued at 166,750 led to the insider holds 266,155 shares of the business.
Xiao Ting bought 10,000 shares of ZBIO for $77,600 on Feb 07 ’25. The Director now owns 47,000 shares after completing the transaction at $7.76 per share. On Dec 04 ’24, another insider, MOULDER LEON O JR, who serves as the Chief Executive Officer of the company, bought 45,000 shares for $9.98 each. As a result, the insider paid 449,100 and bolstered with 241,155 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 56.58 while its Price-to-Book (P/B) ratio in mrq is 0.91.
Stock Price History:
Over the past 52 weeks, ZBIO has reached a high of $26.25, while it has fallen to a 52-week low of $5.83. The 50-Day Moving Average of the stock is -10.92%, while the 200-Day Moving Average is calculated to be -44.42%.
Shares Statistics:
A total of 41.79M shares are outstanding, with a floating share count of 10.15M. Insiders hold about 75.71% of the company’s shares, while institutions hold 32.41% stake in the company.
